SG11201810358YA - Compositions and methods for treating negative symptoms in non-schizophrenic patients - Google Patents
Compositions and methods for treating negative symptoms in non-schizophrenic patientsInfo
- Publication number
- SG11201810358YA SG11201810358YA SG11201810358YA SG11201810358YA SG11201810358YA SG 11201810358Y A SG11201810358Y A SG 11201810358YA SG 11201810358Y A SG11201810358Y A SG 11201810358YA SG 11201810358Y A SG11201810358Y A SG 11201810358YA SG 11201810358Y A SG11201810358Y A SG 11201810358YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- compositions
- methods
- pct
- negative symptoms
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 208000024891 symptom Diseases 0.000 title abstract 3
- 230000000698 schizophrenic effect Effects 0.000 title 1
- 102220240796 rs553605556 Human genes 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 241000551546 Minerva Species 0.000 abstract 1
- 238000003759 clinical diagnosis Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229940068196 placebo Drugs 0.000 abstract 1
- 239000000902 placebo Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Bautinismarcote7 P14cebo 511N•10132 mg ME4 4-101 6 4 mg 31.5 (4.7) 31.7 (4.2) 31.4 (4.3) 3 a ----------- .:;. ' - - - - - - - - - - - - — 4 --------------------- -Placebo - 32 mg --MIN-101 54 mg p-valor: 0.05; ** - 50.01 vows Omen 145087900 vl N 0 *It W O 20 17 / 205 393 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 November 2017 (30.11.2017) WIPO I PCT oimiolollm inn Him!! oniniou oimIE (10) International Publication Number WO 2017/205393 Al (51) International Patent Classification: A61K 31/454 (2006.01) A61P 25/16 (2006.01) A61P 25/00 (2006.01) A61P 25/24 (2006.01) A61P 25/28 (2006.01) (21) International Application Number: PCT/US2017/034030 (22) International Filing Date: 23 May 2017 (23.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/341,590 25 May 2016 (25.05.2016) US (71) Applicant: MINERVA NEUROSCIENCES, INC. [US/US]; 1601 Trapelo Road, Suite 284, Waltham, Massa- chusetts 02451 (US). (72) Inventors: LUTHRINGER, Remy; 2 me de Jargonnant, 1207 Geneva (CH). DAVIDSON, Michael; 11 B Nitzana Street, Apt. 10, 6811713 Tel Aviv (IL). (74) Agent: ERLACHER, Heidi A. et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: COMPOSITIONS AND METHODS FOR TREATING NEGATIVE SYMPTOMS IN NON-SCHIZOPHRENIC PATIEN- TS FIGURE 1 PANSS Negative Symptoms Score (Pentagonal Structure) Change horn Baseline (WARM) (ITT Population) WEEK (57) : The present disclosure describes compositions and methods for treating at least one negative symptom in a human subject who does not have a clinical diagnosis of schizophrenia. The compositions and methods employ a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate or polymorph thereof [Continued on next page] WO 2017/205393 Al MIDEDIMOMOIDEIROIDEM00101011101100111100MEMOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) Published: — with international search report (Art. 21(3))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341590P | 2016-05-25 | 2016-05-25 | |
| PCT/US2017/034030 WO2017205393A1 (en) | 2016-05-25 | 2017-05-23 | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810358YA true SG11201810358YA (en) | 2018-12-28 |
Family
ID=58794265
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810358YA SG11201810358YA (en) | 2016-05-25 | 2017-05-23 | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
| SG10202011470UA SG10202011470UA (en) | 2016-05-25 | 2017-05-23 | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202011470UA SG10202011470UA (en) | 2016-05-25 | 2017-05-23 | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190216793A1 (en) |
| EP (1) | EP3463356A1 (en) |
| JP (2) | JP2019516756A (en) |
| KR (2) | KR20240005110A (en) |
| CN (3) | CN113908156A (en) |
| PH (1) | PH12018502445A1 (en) |
| SG (2) | SG11201810358YA (en) |
| TW (2) | TW202335672A (en) |
| WO (1) | WO2017205393A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201791226A1 (en) | 2014-12-02 | 2017-09-29 | Минерва Ньюросайенсиз, Инк. | COMPOSITIONS CONTAINING 2 - ((1- (2- (4-Fluoro-phenyl) -2-OXOETHYL) PIPERIDIN-4-IL) METHYL) IZOINDOLIN-1-OH FOR TREATING SCHIZOPHRENIA |
| BR112019027398A2 (en) | 2017-06-21 | 2020-07-07 | Minerva Neurosciences, Inc. | gastro-resistant controlled-release oral dosage forms |
| WO2020041504A1 (en) * | 2018-08-21 | 2020-02-27 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
| KR102360137B1 (en) * | 2020-03-25 | 2022-02-08 | 주식회사 케이티앤지 | Cartridge and Aerosol generating device comprising thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60129210T2 (en) * | 2000-02-29 | 2008-03-20 | Mitsubishi Pharma Corp. | CYCLIC AMID DERIVATIVES |
| EP1986647A4 (en) * | 2006-02-07 | 2009-09-02 | Mitsubishi Tanabe Pharma Corp | 4-acylaminopyridine derivative mediated neurogenesis |
| CN101273982A (en) * | 2007-03-30 | 2008-10-01 | 田边三菱制药株式会社 | Medicament for preventing or/and treating depression |
| PT2595484T (en) * | 2010-07-20 | 2018-01-22 | Minerva Neurosciences Inc | Use of cyclic amide derivatives to treat sleep disorders |
| US8937900B2 (en) * | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
| US20130274290A1 (en) * | 2010-07-20 | 2013-10-17 | Cyrenaic Pharmaceuticals, Inc. | Methods of use of cyclic amide derivatives to treat sigma receptor mediated disorders |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| US10208046B2 (en) * | 2014-05-16 | 2019-02-19 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| EA201791226A1 (en) | 2014-12-02 | 2017-09-29 | Минерва Ньюросайенсиз, Инк. | COMPOSITIONS CONTAINING 2 - ((1- (2- (4-Fluoro-phenyl) -2-OXOETHYL) PIPERIDIN-4-IL) METHYL) IZOINDOLIN-1-OH FOR TREATING SCHIZOPHRENIA |
-
2017
- 2017-05-23 SG SG11201810358YA patent/SG11201810358YA/en unknown
- 2017-05-23 WO PCT/US2017/034030 patent/WO2017205393A1/en unknown
- 2017-05-23 CN CN202111014298.8A patent/CN113908156A/en active Pending
- 2017-05-23 JP JP2018561528A patent/JP2019516756A/en active Pending
- 2017-05-23 CN CN201780045461.2A patent/CN109689055A/en active Pending
- 2017-05-23 KR KR1020237043697A patent/KR20240005110A/en active Search and Examination
- 2017-05-23 US US16/302,722 patent/US20190216793A1/en not_active Abandoned
- 2017-05-23 CN CN202111014262.XA patent/CN113694065A/en active Pending
- 2017-05-23 SG SG10202011470UA patent/SG10202011470UA/en unknown
- 2017-05-23 TW TW112118953A patent/TW202335672A/en unknown
- 2017-05-23 EP EP17726525.3A patent/EP3463356A1/en active Pending
- 2017-05-23 TW TW106117023A patent/TWI820001B/en active
- 2017-05-23 KR KR1020187036656A patent/KR20190013846A/en not_active IP Right Cessation
-
2018
- 2018-11-20 PH PH12018502445A patent/PH12018502445A1/en unknown
-
2022
- 2022-05-26 US US17/825,783 patent/US20230190726A1/en active Pending
- 2022-10-04 JP JP2022160201A patent/JP2022188185A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113694065A (en) | 2021-11-26 |
| TW202335672A (en) | 2023-09-16 |
| EP3463356A1 (en) | 2019-04-10 |
| TW201808288A (en) | 2018-03-16 |
| WO2017205393A1 (en) | 2017-11-30 |
| US20190216793A1 (en) | 2019-07-18 |
| CN113908156A (en) | 2022-01-11 |
| KR20240005110A (en) | 2024-01-11 |
| TWI820001B (en) | 2023-11-01 |
| US20230190726A1 (en) | 2023-06-22 |
| CN109689055A (en) | 2019-04-26 |
| SG10202011470UA (en) | 2021-01-28 |
| JP2022188185A (en) | 2022-12-20 |
| KR20190013846A (en) | 2019-02-11 |
| JP2019516756A (en) | 2019-06-20 |
| PH12018502445A1 (en) | 2019-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201408067YA (en) | Crystalline forms of a bruton's tyrosine kinase inhibitor | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201805380YA (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201810358YA (en) | Compositions and methods for treating negative symptoms in non-schizophrenic patients | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201808830YA (en) | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201909224QA (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors |